Literature DB >> 7044592

The clinical pharmacology of VM26 and VP16-213. A brief overview.

P J Creaven.   

Abstract

Mesh：

Substances：

Year:  1982        PMID： 7044592     DOI： 10.1007/bf00254535

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  25 in total

1.  Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.

Authors:  L M Allen; P J Creaven
Journal:  Eur J Cancer       Date:  1975-10       Impact factor: 9.162

2.  PHASE I clinical trial of an oral solution of VP-16-213.

Authors:  N I Nissen; P Dombernowsky; H H Hansen; V Larsen
Journal:  Cancer Treat Rep       Date:  1976-07

3.  VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

Authors:  F Cavalli; R W Sonntag; F Jungi; H J Senn; K W Brunner
Journal:  Cancer Treat Rep       Date:  1978-03

Review 4.  VM 26 and VP 16-213: a comparative analysis.

Authors:  M Rozencweig; D D Von Hoff; J E Henney; F M Muggia
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

5.  Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

Authors:  N I Nissen; V Larsen; H Pedersen; K Thomsen
Journal:  Cancer Chemother Rep       Date:  1972-12

6.  The role of drug disposition kinetics on cellular transport of the antineoplastic agent VM-26.

Authors:  L Allen
Journal:  Drug Metab Rev       Date:  1978       Impact factor: 4.518

7.  Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography.

Authors:  R J Strife; I Jardine; M Colvin
Journal:  J Chromatogr       Date:  1980-05-09

8.  PTG, a new antineoplastic epipodyphyllotoxin.

Authors:  P J Creaven; L M Allen
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

Review 9.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 10.  Etoposide (VP-16-213).

Authors:  B F Issell; S T Crooke
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111
View more
  21 in total

1.  Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.

Authors:  P B Jensen; H Roed; T Skovsgaard; E Friche; L Vindeløv; H H Hansen; M Spang-Thomsen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

3.  Drug monitoring of etoposide (VP16-213). I. A combined method of liquid chromatography and mass spectrometry.

Authors:  H Danigel; K H Pflüger; H Jungclas; L Schmidt; J Dellbrügge
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide.

Authors:  K H Pflüger; L Schmidt; M Merkel; H Jungclas; K Havemann
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.

Authors:  P Canal; R Bugat; C Michel; H Roche; G Soula; P F Combes
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.

Authors:  Moon Ki Choi; Eun Suk Kang; Dae Won Kim; Yonug Hyeh Ko; Hyeri Seok; Jin Hong Park; Dae Hee Pyo; Do Hoon Lim; Seok Jin Kim; Won Seog Kim
Journal:  Int J Hematol       Date:  2013-07-19       Impact factor: 2.490

8.  The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.

Authors:  H Roed; L L Vindelov; I J Christensen; M Spang-Thomsen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions.

Authors:  K H Pflüger; M Hahn; J B Holz; L Schmidt; P Köhl; H W Fritsch; H Jungclas; K Havemann
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J M Dennery; R Belanger; J Gerin-Lajoie; V Montpetit; D Nundy; J Prior; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.